Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PLUS THERAPEUTICS Inc. PSTV

Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases.


Recent & Breaking News (NDAQ:PSTV)

Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹⁸⁶Re) Obisbemeda for the Treatment of Leptomeningeal Metastases

GlobeNewswire 5 days ago

Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

GlobeNewswire January 18, 2023

Plus Therapeutics Provides Updates on ReSPECT(TM) Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

GlobeNewswire November 19, 2022

Plus Therapeutics to Provide Update on ReSPECT(TM) Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

GlobeNewswire November 2, 2022

Plus Therapeutics Announces Selection of "Rhenium (186Re) Obisbemeda" as International Non-Proprietary Name for 186RNL

GlobeNewswire October 26, 2022

Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

GlobeNewswire October 20, 2022

Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress

GlobeNewswire October 19, 2022

Plus Therapeutics to Present at the ThinkEquity Conference

GlobeNewswire October 18, 2022

Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022

GlobeNewswire October 6, 2022

Plus Therapeutics Announces Patient Webinar in Recognition of Breast Cancer Awareness Month

GlobeNewswire October 5, 2022

Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT(TM) Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine

GlobeNewswire October 4, 2022

Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas

GlobeNewswire September 22, 2022

Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022

GlobeNewswire September 12, 2022

Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 8, 2022

Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate

GlobeNewswire September 6, 2022

Plus Therapeutics Announces Summary of FDA Meeting on Company's cGMP Manufacturing Process for Lead Drug Candidate

GlobeNewswire August 29, 2022

Plus Therapeutics to Present Data from ReSPECT-GBM(TM) Clinical Trial at the European Society for Medical Oncology Congress 2022

GlobeNewswire August 23, 2022

Plus Therapeutics Awarded $17.6 Million from State of Texas

GlobeNewswire August 17, 2022

Plus Therapeutics Announces Share Repurchase Program

GlobeNewswire August 15, 2022

Plus Therapeutics Presents Positive Data from Ongoing ReSPECT(TM) Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

GlobeNewswire August 13, 2022